{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:23:35Z","timestamp":1768253015034,"version":"3.49.0"},"reference-count":58,"publisher":"Akademiai Kiado Zrt.","issue":"2","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["AMicr"],"published-print":{"date-parts":[[2021,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Widespread introduction of HIV integrase inhibitors into clinical care may result in appearance of drug resistance mutations affecting treatment outcome. The aim of our study was to monitor the resistance patterns of integrase inhibitors beside protease and reverse transcriptase inhibitors in newly diagnosed therapy-naive HIV-positive patients in Hungary between 2017 and 2019.<\/jats:p><jats:p>Genotype-based resistance testing of HIV integrase, protease and reverse transcriptase was performed by amplification and Sanger population sequencing from plasma samples. Drug resistance mutations were identified by the algorithm of Stanford HIV Drug Resistance Database.<\/jats:p><jats:p>Potentially transmitted, non-polymorphic integrase major mutation was detected in 1 out of 249 samples, while accessory mutations were observed in further 31 patients (12.4%). The overall prevalence of transmitted drug resistance (TDR) mutations related to protease and reverse transcriptase inhibitors was 5.8% (10\/173) between the end of 2017 and 2019. Nucleoside reverse transcriptase inhibitor associated resistance mutations were the most frequent indicators of TDR (6\/173; 3.5%), followed by resistance mutations associated with protease (3\/173; 1.7%) and non-nucleoside reverse transcriptase inhibitors (2\/173, 1.2%).<\/jats:p><jats:p>The first detection of integrase major mutation and the changing patterns of other resistance mutations in Hungarian untreated HIV-positive population indicate the necessity of continuous molecular surveillance of Hungarian HIV epidemic.<\/jats:p>","DOI":"10.1556\/030.2021.01433","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T09:30:08Z","timestamp":1623663008000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary"],"prefix":"10.1556","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-4077","authenticated-orcid":true,"given":"\u00c9va","family":"\u00c1y","sequence":"first","affiliation":[{"name":"1National Reference Laboratory for Retroviruses, Department of Virology, National Public Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Pocskay","sequence":"additional","affiliation":[{"name":"1National Reference Laboratory for Retroviruses, Department of Virology, National Public Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Botond","family":"Lakatos","sequence":"additional","affiliation":[{"name":"2Department of Infectious Diseases, Center of HIV, National Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Szl\u00e1vik","sequence":"additional","affiliation":[{"name":"2Department of Infectious Diseases, Center of HIV, National Institute of Hematology and Infectious Diseases, South-Pest Central Hospital, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Mezei","sequence":"additional","affiliation":[{"name":"1National Reference Laboratory for Retroviruses, Department of Virology, National Public Health Center, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Min\u00e1rovits","sequence":"additional","affiliation":[{"name":"3Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref141","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"SPREAD programme: primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadell\u00e0","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1468-1293.2009.00747.x","article-title":"Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment","volume":"11","author":"Murillo","year":"2010","journal-title":"HIV Med"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Swiss HIV cohort study: successful prevention of transmission of integrase resistance in the Swiss HIV cohort study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Swiss HIV cohort study: successful prevention of transmission of integrase resistance in the Swiss HIV cohort study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/aid.2011.0077","article-title":"Molecular epidemiological analysis of env and pol sequences in newly diagnosed HIV type 1-infected, untreated patients in Hungary","volume":"27","author":"Mezei","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2017.04.012","article-title":"HIV-1 integrase inhibitor resistance among treatment naive patients in the West of Scotland","volume":"92","author":"Bradley-Stewart","year":"2017","journal-title":"J Clin Virol"},{"key":"ref321","article-title":"https www unaids org en resources fact sheet","author":"January","year":"2021"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1468-1293.2009.00747.x","article-title":"Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment","volume":"11","author":"Murillo","year":"2010","journal-title":"HIV Med"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1093\/ofid\/ofy210.567","article-title":"Efficacy and tolerability of integrase inhibitors: experiences from a nationwide real-life cohort","volume":"5","author":"Lakatos","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/QAD.0000000000000119","article-title":"The increasing genetic diversity of HIV-1 in the UK, 2002\u20132010","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dkaa309","article-title":"Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK","volume":"75","author":"Mbisa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/157016209788347976","article-title":"Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention","volume":"7","author":"Kiertiburanakul","year":"2009","journal-title":"Curr HIV Res"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.meegid.2016.06.033","article-title":"Molecular epidemiology of HIV-1 infection in Europe: an overview","volume":"46","author":"Beloukas","year":"2016","journal-title":"Infect Genet Evol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/157016209788347976","article-title":"Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention","volume":"7","author":"Kiertiburanakul","year":"2009","journal-title":"Curr HIV Res"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1071\/SH09041","article-title":"An HIV-1 integrase genotype assay for the detection of drug resistance mutations","volume":"6","author":"Hearps","year":"2009","journal-title":"Sex Health"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/jmv.23572","article-title":"Transmitted HIV drug resistance in treatment-naive Romanian patients","volume":"85","author":"Temereanca","year":"2013","journal-title":"J Med Virol"},{"key":"ref131","volume-title":"Epitools epidemiological calculators","author":"Sergeant","year":"2017"},{"key":"ref311","first-page":"29","article-title":"Global mortality and morbidity of HIV\/AIDS","volume-title":"Major Infectious Diseases","author":"Danforth","year":"2017"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.meegid.2016.12.019","article-title":"Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland","volume":"49","author":"Parczewski","year":"2017","journal-title":"Infect Genet Evol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"e0196670","DOI":"10.1371\/journal.pone.0196670","article-title":"HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011\u20132016 update","volume":"13","author":"Lunar","year":"2018","journal-title":"PLoS One"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"CoRIS: surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice","volume":"74","author":"Alvarez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"ref441","volume-title":"Epitools epidemiological calculators","author":"Sergeant","year":"2017"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jgar.2019.08.024","article-title":"Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naive patients: a single-centre experience","volume":"20","author":"Mazzuti","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fvl-2019-0077","article-title":"Update on HIV integrase inhibitors for the treatment of HIV-1 infection","volume":"14","author":"Max","year":"2019","journal-title":"Future Virol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2008.07.008","article-title":"A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes","volume":"153","author":"Van Laethem","year":"2008","journal-title":"J Virol Methods"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/QAD.0000000000000119","article-title":"The increasing genetic diversity of HIV-1 in the UK, 2002\u20132010","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/QAD.0000000000002355","article-title":"Global, regional and country-level 90-90-90 estimates for 2018: assessing progress towards the 2020 target","volume":"33","author":"Marsh","year":"2019","journal-title":"AIDS"},{"key":"ref01","first-page":"29","article-title":"Global mortality and morbidity of HIV\/AIDS","volume-title":"Major Infectious Diseases","author":"Danforth","year":"2017"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fvl-2019-0077","article-title":"Update on HIV integrase inhibitors for the treatment of HIV-1 infection","volume":"14","author":"Max","year":"2019","journal-title":"Future Virol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s15010-016-0936-5","article-title":"Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013","volume":"45","author":"Zoufaly","year":"2017","journal-title":"Infection"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1071\/SH09041","article-title":"An HIV-1 integrase genotype assay for the detection of drug resistance mutations","volume":"6","author":"Hearps","year":"2009","journal-title":"Sex Health"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/aid.2011.0077","article-title":"Molecular epidemiological analysis of env and pol sequences in newly diagnosed HIV type 1-infected, untreated patients in Hungary","volume":"27","author":"Mezei","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2017.04.012","article-title":"HIV-1 integrase inhibitor resistance among treatment naive patients in the West of Scotland","volume":"92","author":"Bradley-Stewart","year":"2017","journal-title":"J Clin Virol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.meegid.2016.12.019","article-title":"Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland","volume":"49","author":"Parczewski","year":"2017","journal-title":"Infect Genet Evol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jgar.2019.08.024","article-title":"Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naive patients: a single-centre experience","volume":"20","author":"Mazzuti","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"ref11","article-title":"https www unaids org en resources fact sheet","author":"January","year":"2021"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1093\/ofid\/ofy210.567","article-title":"Efficacy and tolerability of integrase inhibitors: experiences from a nationwide real-life cohort","volume":"5","author":"Lakatos","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"17307","DOI":"10.1038\/s41598-019-53520-8","article-title":"Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia","volume":"9","author":"Oroz","year":"2019","journal-title":"Sci Rep"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"e0206234","DOI":"10.1371\/journal.pone.0206234","article-title":"Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: results from the national molecular surveillance of new HIV-diagnoses","volume":"13","author":"Hauser","year":"2018","journal-title":"PLoS One"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"SPREAD programme: primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadell\u00e0","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2008.07.008","article-title":"A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes","volume":"153","author":"Van Laethem","year":"2008","journal-title":"J Virol Methods"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/jmv.23572","article-title":"Transmitted HIV drug resistance in treatment-naive Romanian patients","volume":"85","author":"Temereanca","year":"2013","journal-title":"J Med Virol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jgar.2019.07.014","article-title":"Transmitted drug resistance in newly diagnosed and treatment-na\u00efve HIV type 1-infected patients in Hungary","volume":"20","author":"\u00c1y","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/QAD.0000000000002355","article-title":"Global, regional and country-level 90-90-90 estimates for 2018: assessing progress towards the 2020 target","volume":"33","author":"Marsh","year":"2019","journal-title":"AIDS"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/QAD.0b013e32832b7dca","article-title":"Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis","volume":"23","author":"Attia","year":"2009","journal-title":"AIDS"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dkaa309","article-title":"Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK","volume":"75","author":"Mbisa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s15010-016-0936-5","article-title":"Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013","volume":"45","author":"Zoufaly","year":"2017","journal-title":"Infection"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jgar.2019.07.014","article-title":"Transmitted drug resistance in newly diagnosed and treatment-na\u00efve HIV type 1-infected patients in Hungary","volume":"20","author":"\u00c1y","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"CoRIS: surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice","volume":"74","author":"Alvarez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.meegid.2016.06.033","article-title":"Molecular epidemiology of HIV-1 infection in Europe: an overview","volume":"46","author":"Beloukas","year":"2016","journal-title":"Infect Genet Evol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/QAD.0b013e32832b7dca","article-title":"Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis","volume":"23","author":"Attia","year":"2009","journal-title":"AIDS"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"e0206234","DOI":"10.1371\/journal.pone.0206234","article-title":"Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: results from the national molecular surveillance of new HIV-diagnoses","volume":"13","author":"Hauser","year":"2018","journal-title":"PLoS One"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"e0196670","DOI":"10.1371\/journal.pone.0196670","article-title":"HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011\u20132016 update","volume":"13","author":"Lunar","year":"2018","journal-title":"PLoS One"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"17307","DOI":"10.1038\/s41598-019-53520-8","article-title":"Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia","volume":"9","author":"Oroz","year":"2019","journal-title":"Sci Rep"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/68\/2\/article-p87.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/68\/2\/article-p87.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:17:36Z","timestamp":1651537056000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/68\/2\/article-p87.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":58,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1556\/030.2021.01433","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}